ArticleJournal of neuroendocrinology2026
Biomarker-directed aptamer panels for diagnosis and differentiation of neuroendocrine tumors.
Article in Journal of neuroendocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Biomarker-directed aptamer panels for diagnosis and differentiation of neuroendocrine tumors.Journal of neuroendocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Neuroendocrine tumors (NETs) are rare tumors that may arise in the small intestine (siNET) or pancreas (pNET). The tumors have heterogeneous clinical characteristics, and diagnosis may be challenging. Current non-invasive biomarkers perform suboptimally, and novel biomarkers are highly needed. We aimed to investigate the use of RNA aptamer panels, selected by the APTASHAPE technology, in distinguishing healthy individuals from individuals with NET as well as discriminating siNET from pNET. Plasma samples from 68 individuals with NET and 24 healthy individuals were collected and randomly divided into a development set and a test set. A panel of aptamers recognizing disease-specific plasma proteins was selected in the development set, and the accuracy for disease prediction was evaluated in the test set. The aptamer panels demonstrated high discriminative power, accurately distinguishing between healthy individuals and NET patients with AUCs of 0.74 and 0.87 in the development set and test set, respectively. Furthermore, the aptamer panels were able to differentiate between siNET and pNET patients with AUCs of 0.72 in both the development set and the test set. In addition, mass spectrometry analysis identified ITIH2 and IGHG3 as potential novel biomarkers for the diagnosis of NET. The APTASHAPE platform is a capable tool for selecting protein biomarker-directed aptamer panels for the diagnosis of NET and discrimination between siNET and pNET. Furthermore, the identification of ITIH2 and IGHG3 highlights the potential of APTASHAPE to identify novel protein biomarkers in NET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.